Abraham Gitterman focuses on FDA and Healthcare regulatory, compliance, and fraud and abuse matters involving pharmaceutical and medical device manufacturers. He regularly counsels clients on FDA-regulated advertising and promotion, including use of social media; compliant medical affairs activities, including continuing medical education (CME); appropriate interactions with healthcare professionals; and mobile health applications. Mr. Gitterman also assists with extensive reviews of corporate compliance programs, both generally and pursuant to Corporate Integrity Agreements (CIAs) with OIG, for various life science companies and healthcare entities to ensure compliance with the Anti-Kickback Statute; the False Claims Act; and the Federal Food, Drug, and Cosmetic Act. Mr. Gitterman also has extensive experience counseling clients on the Physician Payments Sunshine Act and related state transparency and "gift ban" laws. He also advises clients on compliance with the Drug Supply Chain Security Act (DSCSA) and the Compounding Quality Act. Prior to joining the firm, Mr. Gitterman was a research associate at a national ACCME-accredited CME provider, where he assisted drafting medical education grant applications and evaluated various conflict of interest policies regarding physician relationships with manufacturers. Mr. Gitterman received a Health Law Certificate from the Law & Health Care Program at the University of Maryland Francis King Carey School of Law. During law school, Mr. Gitterman clerked with the US Department of Justice, Consumer Protection Branch; The Office of Counsel to the Inspector General for the Department of Health and Human Services (OCIG); and The FDA Office of Policy. Mr. Gitterman also founded the Health Law Regulatory & Compliance Competition.